#CannaNova #LLC #announces #formation #CannaNova
GREENSBORO, N.C., July 19, 2022 (GLOBE NEWSWIRE) — CannaNova cannabinoid film
CannaNova LLC today announced its formation to expand the consumer cannabinoid space with DepoFilm™ technology. With DepoFilm™, CannaNova manufactures buccal cannabinoid films for consumers.
CannaNova’s mission is to apply the principles of drug delivery and its second-generation oral film technology, DepoFilm™, to develop and commercialize high-performance cannabis consumables.
Joseph Fuisz, CEO of CannaNova, commented, “CannaNova uses DepofIlm™ technology to address the key challenges facing consumer cannabinoid products today. These include: slow onset, low bioavailability, and inconsistent bioavailability from patient to patient. We also believe that many adult consumers prefer a non-confectionary format.”
“We believe that a rapid onset of action is particularly beneficial in allowing adult consumers to enjoy cannabinoids at the desired dose. A slow onset is fundamentally at odds with dose titration. Too often consumers take supplemental edibles while mistaking a slow onset of action for underdosing.”
“Our hemp-derived products are sold in child-resistant blister cards of eight.”
CannaNova CSO Madhu Hariharan commented, “We are excited to introduce our next-generation film technology, DepoFilm™, to the consumer cannabinoid category. Cannanova was formed to bring our drug delivery expertise and patented technology to the consumer cannabinoid sector.”
“Consumers prefer our fast-acting, mucoadhesive buccal films to traditional means of cannabinoid consumption.”
“In addition to these benefits, DepoFilm™ technology also enables us to produce compelling film shapes with high brand equity that reflect the quality of our adult consumer products.”
CannaNova plans to launch a limited test market under its DeltaFilm™ brand.
About CannaNova LLC:
CannaNova LLC develops, manufactures and markets…
Read on GNW: CannaNova LLC announces its formation; CannaNova will
